

To: Potential SMRI treatment trials grantees

From: Mark Weiser M.D., Associate Director for Treatment Trials, SMRI

SMRI is soliciting applications for treatment trials of biological interventions which may be useful for improving the symptoms of individuals with schizophrenia or bipolar disorder.

This will be a two-stage process. Please send an email with a summary of your idea, up to 350 words, by October 15, 2025, to the treatment trials administrator at bowcutj@stanleyresearch.org.

If your project is of interest, you will be asked to submit a full application.

In the summary please include an estimated, non-itemized total budget. There is no limit to the budget of any given study, but our funds are limited, and we value frugality.

SMRI is most interested in supporting research on the efficacy of drugs which act on the immune system or infectious agents, but we are ultimately interested in the best ideas available, related or not to immune hypotheses.

SMRI aims to support clinical trials testing the efficacy of compounds or biological interventions. Although studies can include a psychosocial component, studies that have a psychosocial intervention as the primary focus will not be considered, nor will apps, analyses of existing data sets, alternative modes of administering existing medications, or drugs focused on alleviating side effects of existing medications. Applications should include information regarding whether the proposed compound crosses the blood brain barrier, with supporting data. If the compound does not cross the blood brain barrier, explanation will be needed as to why the compound could be helpful for treating schizophrenia or bipolar disorder.

We can only fund studies that can be finished and have results in no more than 5 years after funding. If you cannot guarantee that your study will be finished, data analyzed and results available within 5 years of funding, please do not submit a proposal. Progress of funded studies will be monitored in an ongoing fashion, and if it becomes clear that a study will not be completed on time, it will be terminated.

For a list of drugs that are currently being investigated or have been funded in the past, please refer to <http://www.stanleyresearch.org/treatment-trials/awarded-treatment-trials/>.

Please send us your best ideas.

Mark Weiser, M.D.
Associate Director for Treatment Trials
The Stanley Medical Research Institute
<https://www.stanleyresearch.org/>
E-mail: weiserm@stanleyresearch.org
Phone: +972-52-6666570